Kidney PATIENT Act of 2024

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 10545, American Relief Act, 2025

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the Medicare Secondary Payer Act, including HR 6860 and S. 5018, Restore Protections for Dialysis Patients Act; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act, H.R. 5074/S. 4510; issues related to home dialysis.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 S. 4469, A bill to improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes S. 4510 - The Kidney Patient Act Issues related to patient access to infection prevention.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) final rule

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) final rule

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Living Donor Protection Act (H.R. 2923 / S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027/S.4469) Honor Our Living Donors Act (H.R. 6020) Medigap Expansion Act Restore Protections for Dialysis Patients Act (H.R. 6860, S.5081) Expressing support for the designation of the last Tuesday of April each year as "APOL1-Mediated Kidney Disease (AMKD) Awareness Day" (H.Res.1124) Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 (H.R. 5074, S. 4510) PASTEUR Act (H.R. 2940/S. 1355) Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2023 The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323) The CARING for Social Determinants Act of 2023 (H.R. 1066) End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.6860/ S. 5018 Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510, Kidney Patient Act of 2023 H.R. 8594 - Restore Protections for Dialysis Patients Act, all provisions S. 4750 - Restore Protections for Dialysis Patients Act, all provisions H.R.5027 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2023

Client expense: $1,500,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074, the Kidney Patient Act S 4510, the Kidney Patient Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074/S 4510, The Kidney Patient Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare ESRD benefit and chronic kidney disease management. H.R.5074/S.4510 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to reimbursement for treatment of End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S.5018, Restore Protections for Dialysis Patients Act H.R. 5074/S.4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to access to treatment for End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S.5018, Restore Protections for Dialysis Patients Act H.R. 5074/S.4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to access to treatment for End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to reimbursement for treatment of End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 8075, Improving Access to Home Dialysis Act. S. 2407, H.R. 4818, the "Treat and Reduce Obesity Act" S. 1832, H.R. 3842, "Expanding Access to Diabetes Self-Management Training Act" H.R. 5074, S. 4510 "Kidney PATIENT Act of 2023" H.R. 6860, S. 5018 "Restore Protections for Dialysis Patients Act." H.R. 7856, S. 4094, "PREVENT Diabetes Act." Inflation Reduction Act Medicare drug pricing, including Medicare Part D Redesign Program Guidance. Support for Medicare Part D Protected Classes coverage. Kidney patient health and management under Medicare Advantage. Medicare activities and coverage for COVID-19 patients. Protect Medicaid eligibility. Activities regarding implementation of HHS Advancing American Kidney Health Initiative. Activities to address rural health access and quality. Comments on Medicare $2 Drug List Model RFI.

Client expense: $95,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to Centers for Medicare and Medicaid Innovation (CMMI) models; Medicare concurrent hospice and dialysis; Issues relating to staffing and workforce; Issues related to Medicare reimbursement; Kidney PATIENT Act (H.R. 5074/S. 4510); Home dialysis policies.

Client expense: Not reported · Firm income: $90,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to Centers for Medicare and Medicaid Innovation (CMMI) models; Medicare concurrent hospice and dialysis; Issues relating to staffing and workforce; Issues related to Medicare reimbursement; Home dialysis policies; Kidney Patient Act (H.R. 5074/S. 4510).

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

Client expense: $670,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

Client expense: $670,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to End-Stage Renal Disease, dialysis treatment, and coordinated care, including H.R.6860, Restore Protections for Dialysis Patients Act, and S.4469, The Chronic Kidney Disease Improvement in Research and Treatment Act, and S.4510, the Kidney PATIENT Act of 2024.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074, the Kidney Patient Act S 4510, the Kidney Patient Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)

Client expense: $280,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 S. 4469, A bill to improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes S. 4510 - The Kidney Patient Act Issues related to patient access to infection prevention.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) proposed rule

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) proposed rule

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.6860/ S. 5018 - Restore Protections for Dialysis Patients Act H.R.5074/ S.4510 - Kidney PATIENT Act of 2023 H.R.5027 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 Veterans Affairs dialysis services

Client expense: $1,320,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

Living Donor Protection Act (H.R. 2923 / S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027/S.4469) Honor Our Living Donors Act (H.R. 6020) Medigap Expansion Act Restore Protections for Dialysis Patients Act (H.R. 6860, S.5081) Expressing support for the designation of the last Tuesday of April each year as "APOL1-Mediated Kidney Disease (AMKD) Awareness Day" (H.Res.1124) Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 (H.R. 5074, S. 4510) PASTEUR Act (H.R. 2940/S. 1355) Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2023 The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323) The CARING for Social Determinants Act of 2023 (H.R. 1066) End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model

Client expense: $185,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,080,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,080,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 5074/S 4510, The Kidney Patient Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5027/S. 4469 - The Kidney Disease Improvement in Research and Treatment Act H.R. 6860/S. 5018 - Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510 - Kidney PATIENT Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to Centers for Medicare and Medicaid Innovation (CMMI) models; Medicare concurrent hospice and dialysis; Issues relating to staffing and workforce; Issues related to Medicare reimbursement; Kidney PATIENT Act (H.R. 5074/S. 4510); Home dialysis policies.

Client expense: Not reported · Firm income: $90,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to Centers for Medicare and Medicaid Innovation (CMMI) models; Medicare concurrent hospice and dialysis; Issues relating to staffing and workforce; Issues related to Medicare reimbursement; Home dialysis policies; Kidney Patient Act (H.R. 5074/S. 4510).

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare ESRD benefit and chronic kidney disease management. H.R.5074/S.4510 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 8075, Improving Access to Home Dialysis Act. S. 2407, H.R. 4818, the "Treat and Reduce Obesity Act" S. 1832, H.R. 3842, "Expanding Access to Diabetes Self-Management Training Act" H.R. 5074, S. 4510 "Kidney PATIENT Act of 2023" H.R. 6860, S. 5018 "Restore Protections for Dialysis Patients Act." H.R. 7856, S. 4094, "PREVENT Diabetes Act." Comments to CMS RFI on Alternative Payment Model Update and Increasing Organ Transplant Access (IOTA). Comments on CY 2025 Physican Fee Schedule and Medicare Shared Savings Program. Inflation Reduction Act Medicare drug pricing, including Medicare Part D Redesign Program Guidance. Support for Medicare Part D Protected Classes coverage. Medicare payment for dental services for ESRD beneficiaries receiving dialysis. Kidney patient health and management under Medicare Advantage. Medicare activities and coverage for COVID-19 patients. Protect Medicaid eligibility. Activities regarding implementation of HHS Advancing American Kidney Health Initiative. Activities to address rural health access and quality.

Client expense: $90,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

Client expense: $720,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 5074, The Kidney Patient Act of 2023; H.R. 2407, The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act; H.R.6664, Innovation in Pediatric Drugs Act of 2023; S.3565, Affordable Connectivity Program Extension Act of 2024; S.4510, The Kidney Patient Act of 2024

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE